Interestingly, it has been recently reported that SHP2 inhibition can sensitize oncogene-addicted tumors to retreatment with targeted therapies, including ALK inhibitors, for ALK fusion–positive lung cancer; these effects were observed in preclinical models and patients (65). This evidence concerns the gene ALK and lung cancer.